Early kidney injury markers in patients with seronegative spondyloarthropathies: a cross-sectional comparative study
- 1Department of Rheumatology and Internal Medicine, Wroclaw Medical University
- 2Department of Dermatology, Venereology and Clinical Immunology, 4th Military Clinical Hospital, Wrocław University of Science and Technology
- 3Department of Nephrology, Transplantation and Clinical Immunology, 4th Military Clinical Hospital, Wrocław University of Science and Technology
Abstract
Patients with seronegative spondyloarthropathies (SpA) have an increased risk of kidney involvement. The aim of the study was to assess early kidney injury markers (EKIMs) in SpA patients without clinically recognized kidney disease compared with control group (CG), and to analyze associations with SpA subtypes and therapy. In this cross-sectional study, 125 SpA patients (ankylosing spondylitis, psoriatic arthritis, non-radiographic axial SpA) and 53 GC were included. Serum and urinary NGAL, KIM-1, RBP4, FGF23, NAG, and IL-18 were measured. Our findings indicate subclinical kidney involvement in SpA. Serum and urinary KIM-1 levels were elevated in SpA patients compared to CG (serum: p = 0.039; urine: p = 0.024). Urinary RBP4 was higher in SpA patients (p = 0.005), while serum RBP4 was lower (p < 0.001) compared to CG. Urinary FGF23 concentrations were higher in SpA patients than in CG (p < 0.001). Serum NAG levels differed between SpA and CG (p = 0.018). While no overall differences were observed for urinary NGAL or IL-18 between the SpA group and CG, subgroup analyses revealed specific differences. Psoriatic arthritis patients showed distinct profiles, including lower serum FGF23 (p = 0.028 vs. nr-axSpA and CG), lower serum NAG (p = 0.013 vs. CG), and higher urinary IL-18 (p = 0.012 vs. CG) compared to CG. Levels of most EKIMs did not significantly differ between patients on first-line versus second-line therapies, except for serum FGF23, which was lower in patients receiving bDMARDs/tsDMARDs (p = 0.018). SpA patients without overt kidney disease demonstrate subclinical tubular injury and altered biomarker profiles, supporting the potential role of EKIMs in early renal assessment.
Related
- Comparative Analysis of Serum C-reactive Protein and Procalcitonin as Diagnostic Markers in Odontogenic Infections: A Cross-Sectional Study.
- Health literacy and successful aging among elderly patients at Kasr Alainy Hospital: a cross-sectional comparative study
- Wrist and Thumb Kinematics During Sustained Smartphone Typing in Patients with Carpal Tunnel Syndrome: A Cross-Sectional Comparative Study
- The Comparative Prognostic Value of the Interim PET Deauville Score and ΔSUVmax in Classical Hodgkin Lymphoma: A Real-World Study of Imaging and Inflammatory Markers
- Speech markers of depression: cross-sectional discrimination, longitudinal association, and treatment response prediction
BibTeX
@article{tyczynska2026early,
title = {{Early kidney injury markers in patients with seronegative spondyloarthropathies: a cross-sectional comparative study}},
author = {Kinga Maria Tyczyńska and Piotr Krzysztof Krajewski and Hanna Augustyniak-Bartosik and Marcelina Żabińska and Dorota Bartoszek and Katarzyna Kościelska-Kasprzak and Jerzy Świerkot},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-59791-2},
url = {https://doi.org/10.1038/s41598-026-59791-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Early kidney injury markers in patients with seronegative spondyloarthropathies: a cross-sectional comparative study
AU - Kinga Maria Tyczyńska
AU - Piotr Krzysztof Krajewski
AU - Hanna Augustyniak-Bartosik
AU - Marcelina Żabińska
AU - Dorota Bartoszek
AU - Katarzyna Kościelska-Kasprzak
AU - Jerzy Świerkot
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-59791-2
UR - https://doi.org/10.1038/s41598-026-59791-2
AB - Patients with seronegative spondyloarthropathies (SpA) have an increased risk of kidney involvement. The aim of the study was to assess early kidney injury markers (EKIMs) in SpA patients without clinically recognized kidney disease compared with control group (CG), and to analyze associations with SpA subtypes and therapy. In this cross-sectional study, 125 SpA patients (ankylosing spondylitis, psoriatic arthritis, non-radiographic axial SpA) and 53 GC were included. Serum and urinary NGAL, KIM-1, RBP4, FGF23, NAG, and IL-18 were measured. Our findings indicate subclinical kidney involvement in SpA. Serum and urinary KIM-1 levels were elevated in SpA patients compared to CG (serum: p = 0.039; urine: p = 0.024). Urinary RBP4 was higher in SpA patients (p = 0.005), while serum RBP4 was lower (p < 0.001) compared to CG. Urinary FGF23 concentrations were higher in SpA patients than in CG (p < 0.001). Serum NAG levels differed between SpA and CG (p = 0.018). While no overall differences were observed for urinary NGAL or IL-18 between the SpA group and CG, subgroup analyses revealed specific differences. Psoriatic arthritis patients showed distinct profiles, including lower serum FGF23 (p = 0.028 vs. nr-axSpA and CG), lower serum NAG (p = 0.013 vs. CG), and higher urinary IL-18 (p = 0.012 vs. CG) compared to CG. Levels of most EKIMs did not significantly differ between patients on first-line versus second-line therapies, except for serum FGF23, which was lower in patients receiving bDMARDs/tsDMARDs (p = 0.018). SpA patients without overt kidney disease demonstrate subclinical tubular injury and altered biomarker profiles, supporting the potential role of EKIMs in early renal assessment.
SN - 2045-2322
ER -